Home / Research Collaborations
Research Collaborations
The platform is for sale as a partner to someone else’s molecule, too.
Research collaborations
Adaptable to someone else’s molecule
ProteoThera’s MB technology platform is widely adaptable for use with proteins, peptides or other small molecules. It can generate new pharmacokinetic profiles for therapies, transforming systemically delivered drugs into locally delivered drugs.
ProteoThera is actively identifying research collaborations. If you are interested in learning how MB technology can transform your therapy, please contact us at info@proteothera.com.
Current collaboration
MIT, on cartilage pharmacokinetics
ProteoThera is collaborating with Massachusetts Institute of Technology professor Alan Grodzinsky, Sc.D. of the Department of Biological Engineering and the Center for Biomedical Engineering, to better understand the pharmacokinetics of matrix-binding fusion proteins within human cartilage.
Technology origin
The matrix-binding protein fusion technology came out of research conducted at Brigham and Women’s Hospital, Harvard Medical School and the Harvard University Department of Stem Cell and Regenerative Biology.
Bring a molecule
The platform works by fusion. If you have a validated protein, peptide or small molecule, the question is whether a matrix-binding domain can be attached without losing activity.